Hongyun T. Zhao

651 Dongfeng East Road
Guangzhou, 510060, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 180 publications

Correction to: Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapy.

Correction to: Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapy.

Journal: BMC cancer

Published: August 13, 2026

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.

Journal: JAMA

Published: August 10, 2026

Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study.

Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 24, 2026

Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial.

Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial.

Journal: JAMA

Published: June 17, 2026

BCL-2/BCL-xL inhibitor pelcitoclax with osimertinib for EGFR-mutated advanced non-small-cell lung cancer: a phase 1b trial.

BCL-2/BCL-xL inhibitor pelcitoclax with osimertinib for EGFR-mutated advanced non-small-cell lung cancer: a phase 1b trial.

Journal: Journal for immunotherapy of cancer

Published: June 03, 2026

Tumor-Agnostic Therapies: Translating Scientific Breakthroughs Into Global Implementation.

Tumor-Agnostic Therapies: Translating Scientific Breakthroughs Into Global Implementation.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 01, 2026

Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial.

Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial.

Journal: The Lancet. Oncology

Published: March 20, 2026

Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study.

Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 04, 2026

Prognostic value of chemotherapy-related mean corpuscular hemoglobin (MCH) kinetics in patients with non-small cell lung cancer receiving adjuvant chemotherapy.

Prognostic value of chemotherapy-related mean corpuscular hemoglobin (MCH) kinetics in patients with non-small cell lung cancer receiving adjuvant chemotherapy.

Journal: Cancer treatment and research communications

Published: November 25, 2025

The Oncogenic EGFR-SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer.

The Oncogenic EGFR-SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer.

Journal: Cancer discovery

Published: November 01, 2025

FAK activation drives non-genetic adaptive survival of ALK-rearranged lung cancer under tyrosine kinase inhibitor treatment.

FAK activation drives non-genetic adaptive survival of ALK-rearranged lung cancer under tyrosine kinase inhibitor treatment.

Journal: Journal of genetics and genomics = Yi chuan xue bao

Published: October 26, 2025

Diverse genomic and transcriptomic heterogeneity in EGFR-mutant lung adenocarcinoma between exon 19 del and exon 21 L858R.

Diverse genomic and transcriptomic heterogeneity in EGFR-mutant lung adenocarcinoma between exon 19 del and exon 21 L858R.

Journal: Cell communication and signaling : CCS

Published: October 14, 2025

Showing 1-12 of 180

Last Updated: 09/26/2026